Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes

Novo Nordisk A/S753 enrolled

Overview

This trial is conducted in Europe. The aim of this trial is to evaluate the safety profile of insulin aspart in subjects with type 1 diabetes having participated in trial ANA/DCD/035.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

753

Conditions

Diabetes Diabetes Mellitus, Type 1

Interventions

insulin aspartDRUG

Injected subcutaneously (s.c, under the skin) as meal time insulin

human soluble insulinDRUG

Injected subcutaneously (s.c, under the skin) as meal time insulin

insulin NPHDRUG

Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * The subject must have completed the six month controlled treatment period in trial ANA/DCD/035

Locations (80)

Outcomes

Primary Outcomes

Number of hypoglycaemic events

Secondary Outcomes

Occurrence of adverse events

Incidence of hypoglycaemic episodes

Standard safety parameters: Haematology and biochemistry

HbA1c (glycosylated haemoglobin)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.